TrialClinical cancer research : an official journal of the American Association for Cancer Research2017

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Jacob D Soumerai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.